Going from thousands of dollars to $50 is a huge change
In a country where the cost of staying healthy has long sorted people into those who can and those who cannot, the Trump administration struck a deal this week with Eli Lilly and Novo Nordisk to lower the price of GLP-1 weight loss drugs and expand their coverage under Medicare and Medicaid. Beginning in January, injectable versions will be available for $350 a month through a new direct-to-consumer platform, with Medicare patients paying as little as $50. The agreement is a genuine shift in access for millions — and yet, as with most things in American healthcare, the relief is real but unevenly distributed, arriving fully only for those already close enough to catch it.
- Millions of Americans have been paying thousands of dollars monthly for GLP-1 drugs, or going without them entirely, because Medicare explicitly banned coverage for weight loss — a prohibition now reversed.
- The new $350 injectable price is lower than the current $500 average, but health policy researchers warn it still exceeds the roughly $100 monthly threshold beyond which many patients stop taking their medications.
- Medicare beneficiaries stand to see the most dramatic change, with co-pays dropping to $50 a month — a transformation for those who were previously paying $3,000 to $4,000 out of pocket.
- The oral pill's $150 introductory price raises questions about where costs will land long-term, and millions without qualifying insurance still face the cash-pay market as their only option.
- Pharmaceutical companies walked away with significant concessions — tariff protection, expedited FDA review for oral versions, and access to a vastly expanded patient base — making this as much a trade as a negotiation.
President Trump announced this week that his administration had reached a deal with Eli Lilly and Novo Nordisk to reduce the price of GLP-1 weight loss drugs and expand insurance coverage for millions of Americans. Starting in January, injectable versions will be available for $350 a month through a new direct-to-consumer platform called TrumpRx, with prices set to fall further to $250 within two years. An oral version, pending FDA approval, is promised at $150 a month. Medicare patients will pay a $50 monthly co-pay, with the government covering the remainder up to roughly $245 a month.
The Medicare shift is the most consequential part of the agreement. Until now, Medicare explicitly prohibited coverage of these drugs for weight loss, leaving older Americans to pay the full cost — often thousands of dollars a month — or go without. That ban is now lifted. Medicaid coverage is also being expanded, opening access to another large population that had largely been shut out.
But the picture is not uniformly bright. Stacie Dusetzina, a health policy researcher at Vanderbilt University, notes that $350 a month still exceeds the threshold — around $100 — at which research shows adherence begins to drop sharply. A $4,200 annual commitment is manageable for some and out of reach for others. The oral pill's $150 price appears to be an introductory rate, and its long-term cost remains unclear. For people whose insurance plans don't cover weight loss as a medical indication, the TrumpRx cash-pay platform may be their only option regardless of price.
The pharmaceutical companies, meanwhile, secured meaningful concessions: protection from a threatened 100 percent tariff on branded drugs, priority FDA review vouchers for their oral medications, and access to millions of new patients through expanded public insurance. The deal, in other words, is a genuine opening — transformative for Medicare beneficiaries who qualify, and a more modest step for everyone else still standing outside the door.
President Trump announced a deal this week with two of the world's largest pharmaceutical companies—Eli Lilly and Novo Nordisk—to bring the price of weight-loss drugs down substantially. Starting in January, Americans who pay out of pocket will be able to buy injectable versions of these medications, known as GLP-1s, for $350 a month through a new direct-to-consumer platform called TrumpRx. That price will drop further to $250 within two years. An oral version, not yet approved by regulators, is promised at $150 a month. For Medicare patients, the picture is even more dramatic: a $50 monthly co-pay, with the government covering the rest up to about $245 a month total.
The scale of this shift cannot be overstated. Until now, Medicare explicitly banned coverage of these drugs for weight loss, even though they were approved for that purpose. Patients who wanted them had to pay the full freight—often thousands of dollars monthly. That prohibition meant millions of older Americans simply could not afford access. The new agreement opens that door. It also expands Medicaid coverage, bringing these medications within reach of another large population that has been locked out.
Yet the details matter enormously, and they complicate the narrative of universal relief. Stacie Dusetzina, a health policy researcher at Vanderbilt University, points out that the $350 monthly price for injectable drugs, while lower than the current $500 average, still sits well above the threshold where many people stop taking medications altogether. Research shows that once a drug costs more than about $100 a month, adherence drops sharply. People make hard choices about what they can afford. A $350 monthly bill, multiplied across twelve months, becomes a $4,200 annual commitment—manageable for some, impossible for others.
The oral pill presents a different puzzle. The $150 price tag appears to be an introductory rate, a foot in the door designed to draw patients in before prices climb. If the price eventually stabilizes near that figure, it could genuinely expand access. But the word "eventually" carries weight. For now, the actual long-term cost remains unclear. Dusetzina notes that for people whose insurance plans do not cover weight loss as a medical indication—and many plans still don't—the cash-pay options through TrumpRx may be the only pathway available, regardless of the price.
The pharmaceutical companies, for their part, have secured substantial gains. They avoid a threatened 100 percent tariff on branded drugs that the Trump administration had dangled as leverage. Both Eli Lilly and Novo Nordisk received priority review vouchers from the FDA, allowing them to move their oral weight-loss medications through the approval process on an expedited track. And they gain access to millions of new patients through the expanded Medicare and Medicaid coverage. What looked like a negotiation, in other words, also looks like a trade: lower prices in exchange for protection from tariffs, regulatory speed, and a vastly enlarged market.
The Medicare expansion is the most consequential piece. A person who was paying $3,000 or $4,000 a month out of pocket now pays $50. That is transformative. But it applies only to Medicare beneficiaries who meet certain medical criteria and who are willing to navigate the enrollment process. For the uninsured and underinsured who fall outside Medicare and Medicaid, the $350 injectable price remains a significant barrier. The deal, in short, is not equally good for everyone. It is very good for some. For others, it opens a door that remains too expensive to walk through.
Notable Quotes
Many people can't afford that amount of money. Research shows that once the price reaches about $100 a month, a lot of people stop taking their medicines.— Stacie Dusetzina, Vanderbilt University
The companies have made out quite well in this deal. They avoid the threat of tariffs, receive priority review vouchers for expedited FDA approval, and get access to many more patients through expanded Medicare and Medicaid coverage.— Stacie Dusetzina, Vanderbilt University
The Hearth Conversation Another angle on the story
So the headline is that prices are dropping. But you're saying it's more complicated than that?
The prices are dropping, yes. But from where to where matters. If you're paying cash and you're not on Medicare, $350 a month is better than $500, but it's still $4,200 a year. That's real money for most people.
And the research shows people bail out around $100 a month?
Right. That's the breaking point where people start choosing between the medication and other bills. So even the "lower" price might still be too high for the people who need help most.
What about the Medicare piece? That sounds genuinely transformative.
It is. Going from thousands of dollars a month to $50 is enormous. But it only applies to Medicare patients who meet certain conditions. And it reverses a ban that had been in place for years.
Why was there a ban in the first place?
When Medicare set up its prescription drug benefit, they decided weight loss wasn't a covered indication. It was a policy choice. This deal reverses that, but only for these specific drugs and only for Medicare.
And the pharmaceutical companies—they're happy with this?
Very happy. They avoid tariffs, they get expedited FDA approval for their oral versions, and they gain access to millions of new patients through Medicare and Medicaid. It's a win for them on multiple fronts.